Rockwell Medical Inc. Common Stock (RMTI)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business: Rockwell Medical sells hemodialysis concentrates and related products, a necessary but unglamorous niche. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $17.8M and net income of -$1.2M. That small loss follows fiscal Q1 2026 (quarter ended 2026-03-31) revenue of $17.3M and net loss of $1.6M. More troubling, full-year figures show fiscal 2025 (period ended 2025-12-31) revenue of $69.3M and net loss of $5.3M, versus fiscal 2024 revenue of $101.5M and net loss of $480,000. Revenue fell materially and losses widened. The company has lost money in each of the last four years, which is why the Lynch screen assigns no category. At a $31.6M market cap and $7.85 close on 2026-10-13, the stock trades at 0.89 times book value per FairStock. That might attract a Graham-style bargain hunter, but a negative P/E and Altman Z-score of -8.38 point to financial distress risk. Debt-to-equity of 0.40 is not overwhelming, and trailing free cash flow of $1.5M gives a 4.9% FCF yield, so there is some cash generation. Still, ROCE of -5.18% and ROE of -15.53% show capital is not earning a return. A true moat would show stable pricing power and consistent profits; here I see none in the numbers. The Piotroski F-score of 6/9 offers a sliver of accounting improvement, but not enough to offset shrinking sales and recurring losses. This is a speculative turnaround, not a compounding business. The asset discount is real, but value investors should demand evidence that losses are ending before calling it cheap.

In plain English: Rockwell Medical makes and sells products used in kidney dialysis. It has lost money in each of the last four years, so the business looks weak. The stock price looks low compared with its assets, but it is not clearly cheap because the company is still unprofitable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer